| Name | Pyrazolo[1,5-a]pyrimidine 4h |
| Description | Pyrazolo[1,5-a]pyrimidine 4h is a morpholine derivative that is a selective antagonist of the adenosine A2A receptor. It has been shown to be neuroprotective in animal models of Parkinson's disease and Huntington's chorea. |
| In vivo | Only Parthenolide, the HDAC inhibitor with anti-inflammatory features, displayed a potent anti-apoptotic effect in Phb1 KO hepatocytes. Indeed, TSA and Parthenolide-treated hepatocytes showed increased levels of FXR, and reduced levels of CYP7A1, HDAC4, TNFα, TRAIL and Bax suggesting a less toxic effect of bile acids as a results of specific HDAC inhibition, resulting in the attenuation of the Phb1 KO hepatocytes apoptotic response. Importantly, Parthenolide exerts a protective effect from the liver injury after BDL in Phb1 KO mice. Indeed, Parthenolide treatment results in a reduction of the mortality rate of this mice after BDL associated with a lower apoptotic response as revealed by a reduction of necrotic areas, Tunel-staining, as well as decreased ALT (8431±957 vs.4225±210 U/L) and AST (4805±300 vs.2242±438 U/L) activities compared to control Phb1 KO mice[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 25 mg/mL (62.27 mM), Sonication is recommended.
|
| Keywords | Pyrazolo[1,5-a]pyrimidine 4h | Pyrazolo[1,5a]pyrimidine 4h | Pyrazolo[1,5 a]pyrimidine 4h |
| Related Compound Libraries | Bioactive Compound Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library |
![Pyrazolo[1,5-a]pyrimidine 4h](/ProductImageEN1/2025-09/Large/d48823d0-c4ec-49c1-9599-1768e166b5a5.png)
United States
